Navigation Links
Celleration, Inc. Announces Close of $8 Million Series E Financing
Date:1/11/2011

EDEN PRAIRIE, Minn., Jan. 11, 2011 /PRNewswire/ -- Celleration, Inc., a privately held medical device company focused on developing and commercializing therapeutic ultrasound products, today announced the closing of an $8 million Series E round of equity financing.  All of the Company's existing institutional investors participated in this round in addition to Sightline Healthcare Opportunity Fund who participated as a new investor.

"The addition of Sightline Healthcare Opportunity Fund as a new investor to our solid base of venture capital partners is a strong endorsement of the team we have built and further validates the potential value of MIST Therapy to all stakeholders in today's cost sensitive healthcare environment," said Mark Wagner, President and CEO of Celleration, Inc.  "This round of financing positions Celleration well for the next phase of growth and market development and provides funding to develop additional applications for MIST Therapy."

About Celleration, Inc.:

Celleration, Inc. is a privately held medical device company. Celleration develops and markets a proprietary technology that has been proven to accelerate healing in wounds by delivering therapeutic, low frequency ultrasound without direct contact of the delivery device to the wound surface.  Celleration's core product, the MIST Therapy® System has been clinically shown to positively impact all critical aspects of the wound healing process providing clinical and economic benefits to institutions treating non-healing wounds.  Currently, over 45,000 patients have been treated with 800 system installations.


'/>"/>
SOURCE Celleration, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. RF Technologies® Announces Distributor Agreement With Universal Hospital Services
2. Nfocus Neuromedical Announces FDA 510(k) Clearance for Next Generation Device to Treat Vascular Lesions
3. Dehaier Medical Announces Participation in Arab Health 2011
4. CareFusion Announces Sale of OnSite Services Instrument Management and Repair Business
5. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
6. Stereotaxis Announces CE Mark and First Human Case for Vdrive™
7. AccessClosure Announces Launch of New Mynx Cadence™ Vascular Closure Device
8. STAAR Surgical Announces Fourth Quarter 2010 Revenue Expected to Exceed $14.2 Million
9. Mithridion, Inc. Announces New Funding and Outlines Strategy for Central Nervous System Drug Development
10. Nalco Announces Price Increase
11. Vasomedical Announces Launch of Its Online Company Store
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015   HeartWare International, Inc . (NASDAQ: ... support technologies that are revolutionizing the treatment of advanced heart ... , is scheduled to present at the Bank of America ... Vegas on Thursday, May 14, 2015, at 10:00 ... of the Company,s presentation at the conference will be available ...
(Date:5/4/2015)... 2015 MEI Pharma, Inc. (Nasdaq: ... clinical development of novel therapies for cancer, today ... the Company,s investigational drug candidate ME-344 in cancer ... with a tyrosine-kinase inhibitor (TKI). In addition, a ... potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) complex ...
(Date:5/4/2015)... 2015 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... for quarter ending March 31, 2015 after market ... host a conference call that day at 5:00 ...
Breaking Medicine Technology:HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3
... The University HealthSystem Consortium (UHC) today announced an agreement with Centurion Service ... services. The contract was effective on February 1, 2010 . , ... Centurion, the world,s largest medical auction house with ... assists UHC members in the setup and management of their surplus asset programs ...
... (NYSE: ABT ) will present at the 26th Annual Sanford Bernstein ... York City .  Miles D. White, chairman and chief executive officer, will make ... , , , ... presentation will be accessible through Abbott,s Investor Relations Web site at www.abbottinvestor.com ...
Cached Medicine Technology:University HealthSystem Consortium Selects Centurion Service Group for Equipment and Asset Liquidation Services 2
(Date:5/4/2015)... and Seattle, WA (PRWEB) May 04, 2015 ... formation of a collaboration to facilitate development of NM108, ... ophthalmic disorders that lead to blindness, including Diabetic Retinopathy. ... MiDROPS™ formulation platform developed by EyeCRO, which can deliver ... via a topical eyedrop. , Under the terms ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Los ... now offering a more comfortable and attractive alternative for ... of choice for those who have lost teeth. Unfortunately, ... feel insecure or slip at the worst possible moment ... or talks. They can also painfully pinch or rub ...
(Date:5/4/2015)... Ticket Down is a reputable source for authentic ... in Charlottesville, VA. McCartney is one of the most ... this beloved performer continues to roll along with no signs ... legendary groups: Wings and The Beatles, has been celebrating his ... the “Out There” tour and has continually added new stops ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Ticket Down is ... the Colonial Life Arena in Columbia, South Carolina. ... continuation of his “Out There” tour which originally kicked off ... tour is North America and the legendary performer recently announced ... the Wells Fargo Arena on June 21st, in Charlottesville, VA ...
(Date:5/4/2015)... 04, 2015 New findings released today ... Association (ABTA) show that people diagnosed with a brain ... options, including clinical trials, at the time of diagnosis, ... difficult decisions about their course of treatment. The release ... first nationwide brain tumor volunteer network, the ABTA CommYOUnity™, ...
Breaking Medicine News(10 mins):Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2Health News:Paul McCartney Tickets at John Paul Jones Arena in Charlottesville, VA: Ticket Down Slashes Paul McCartney Ticket Prices in Charlottesville at the John Paul Jones Arena 2Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3
... In a new report that bucks the concerns raised by ... Public Health (BUSPH) (sph.bu.edu) researcher concludes that electronic cigarettes are ... fight against tobacco-related diseases and death. The review, ... in the Journal of Public Health Policy , is ...
... set a target for the influenza vaccination rate for 2006 ... increase to more than 75% by 2010. These rates have ... In the current issue of Deutsches rzteblatt International ... group around Annicka M. Reuss presents rates from flu seasons ...
... , THURSDAY, Dec. 16 (HealthDay News) -- ... are treated with inhaled corticosteroids may face a significantly ... of diabetes, new Canadian research suggests. The warning ... 380,000 respiratory patients in Quebec. Inhaler use was associated ...
... The Simbiontes ("Symbionts" in English) Project brought together children, ... its kind fundraising project in Portugal. A true symbiosis ... this award for scientific research. Miguel Godinho Ferreira, ... outside Lisbon, is the first scientist to win the ...
... happy holiday thought, but an important one: The number of ... surges by 33 percent on New Year,s Day. The suspected ... by sociologist David Phillips of the University of California, San ... on New Year,s is published in the journal Addiction ...
... HealthDay Reporter , WEDNESDAY, Dec. 15 (HealthDay News) -- ... death diagnosis is not only unnecessary but may make it less ... organs, a new study finds. Researchers reviewed records from the ... children who had been declared brain dead. All of the people ...
Cached Medicine News:Health News:Evidence suggests e-cigs safer than cigarettes, researcher claims 2Health News:Inhalers Linked to Higher Odds of Diabetes in Asthma, COPD Patients 2Health News:Inhalers Linked to Higher Odds of Diabetes in Asthma, COPD Patients 3Health News:Instituto Gulbenkian de Ciencia scientist wins new Portuguese award Simbiontes for cancer research 2Health News:SIDS spikes on New Year's Day 2Health News:Second Brain Death Exam Unnecessary, Study Finds 2Health News:Second Brain Death Exam Unnecessary, Study Finds 3
The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
... REMstar Plus with C-Flex ... controls, and the comfort of ... the REMstar Plus with C-Flex ... to deliver sleep therapy by ...
REMstar Pro with C-Flex is a combination of the advances from our other products. The difference is the C-Flex waveform which offers a more comfortable way to deliver sleep therapy by taking the work...
Low-taper wall construction guarantees error less than 1% absolute, 0.4 hematocrit, relative...
Medicine Products: